256 related articles for article (PubMed ID: 28702469)
21. Risk factors for bloodstream infections due to extended-spectrum β-lactamase producing Enterobacteriaceae in cancer patients.
Ceken S; Iskender G; Gedik H; Duygu F; Mert D; Kaya AH; Altuntas F; Ertek M
J Infect Dev Ctries; 2018 Apr; 12(4):265-272. PubMed ID: 31851636
[TBL] [Abstract][Full Text] [Related]
22. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
Aslan AT; Akova M
Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
[No Abstract] [Full Text] [Related]
23. Clinical Characteristics, Prognosis and Treatment of Bloodstream Infections with
Liu Y; Li F; Fang Y; Zhong Q; Xiao Y; Zheng Y; Zhu J; Zhao C; Cao X; Xiong J; Hu L
Infect Drug Resist; 2024; 17():1811-1825. PubMed ID: 38741943
[TBL] [Abstract][Full Text] [Related]
24. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study.
Harris PNA; Pezzani MD; Gutiérrez-Gutiérrez B; Viale P; Hsueh PR; Ruiz-Garbajosa P; Venditti M; Tumbarello M; Navarro-Francisco C; Calbo E; Akova M; Giamarellou H; Oliver A; Almirante B; Gasch O; Martínez-Martínez L; Schwaber MJ; Daikos G; Pitout J; Peña C; Hernández-Torres A; Doi Y; Pérez F; Tuon FF; Tacconelli E; Carmeli Y; Bonomo RA; Pascual Á; Paterson DL; Rodríguez-Baño J;
Int J Antimicrob Agents; 2017 Nov; 50(5):664-672. PubMed ID: 28782704
[TBL] [Abstract][Full Text] [Related]
25. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
[TBL] [Abstract][Full Text] [Related]
26. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR).
Gudiol C; Royo-Cebrecos C; Tebe C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Carratalà J;
BMJ Open; 2017 Jan; 7(1):e013268. PubMed ID: 28115333
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).
Pierrotti LC; Pérez-Nadales E; Fernández-Ruiz M; Gutiérrez-Gutiérrez B; Tan BH; Carratalà J; Oriol I; Paul M; Cohen-Sinai N; López-Medrano F; San-Juan R; Montejo M; Freire MP; Cordero E; David MD; Merino E; Mehta Steinke S; Grossi PA; Cano Á; Seminari EM; Valerio M; Gunseren F; Rana M; Mularoni A; Martín-Dávila P; van Delden C; Hamiyet Demirkaya M; Koçak Tufan Z; Loeches B; Iyer RN; Soldani F; Eriksson BM; Pilmis B; Rizzi M; Coussement J; Clemente WT; Roilides E; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J; Aguado JM;
Transpl Infect Dis; 2021 Jun; 23(3):e13520. PubMed ID: 33222379
[TBL] [Abstract][Full Text] [Related]
29. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
Pilmis B; Delory T; Groh M; Weiss E; Emirian A; Lecuyer H; Lesprit P; Zahar JR
Int J Infect Dis; 2015 Oct; 39():62-7. PubMed ID: 26327124
[TBL] [Abstract][Full Text] [Related]
30. Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review.
Chastain DB; White BP; Cretella DA; Bland CM
Ann Pharmacother; 2018 May; 52(5):484-492. PubMed ID: 29239220
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.
Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM
Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174
[TBL] [Abstract][Full Text] [Related]
32. Colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis.
Alevizakos M; Karanika S; Detsis M; Mylonakis E
Int J Antimicrob Agents; 2016 Dec; 48(6):647-654. PubMed ID: 27746102
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J;
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145
[TBL] [Abstract][Full Text] [Related]
34. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
[TBL] [Abstract][Full Text] [Related]
35. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
36. Clinical Risk Score for Prediction of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Bloodstream Isolates.
Augustine MR; Testerman TL; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
Infect Control Hosp Epidemiol; 2017 Mar; 38(3):266-272. PubMed ID: 27989244
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of ESBL-Producing Enterobacteriaceae in Pediatric Bloodstream Infections: A Systematic Review and Meta-Analysis.
Flokas ME; Karanika S; Alevizakos M; Mylonakis E
PLoS One; 2017; 12(1):e0171216. PubMed ID: 28141845
[TBL] [Abstract][Full Text] [Related]
38. Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections.
Herrmann J; Burgener-Gasser AV; Goldenberger D; Roth J; Weisser M; Tamma PD; Tschudin-Sutter S
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):213-221. PubMed ID: 37993680
[TBL] [Abstract][Full Text] [Related]
39. Piperacillin-tazobactam as alternative to carbapenems for ICU patients.
Pilmis B; Jullien V; Tabah A; Zahar JR; Brun-Buisson C
Ann Intensive Care; 2017 Nov; 7(1):113. PubMed ID: 29127502
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for treatment failure in patients receiving β-lactam/β-lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study.
Giannella M; Pascale R; Ferraro G; Toschi A; Pancaldi L; Furii F; Bartoletti M; Tedeschi S; Ambretti S; Lewis RE; Viale P
Int J Antimicrob Agents; 2019 May; 53(5):574-581. PubMed ID: 30639527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
